Clinical trials: Corneal Deformity
Sjögren Syndrome, Dry Eye
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
Primary Objective To assess the proportion of patients with Sjögren's dry eye who demonstrate impaired corneal sensitivity. Secondary Objectives To assess corneal sensitivity via Cochet-Bonnet esthesiometer.
- Trial name
- GEMINAE (NCT06411132)
- Testing
- observational study
- Where
- 15 sites in United States
- Volunteers
- 103 people
- Sponsor
- Dompé Farmaceutici S.p.A
Fuchs Endothelial Corneal Dystrophy
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.
- Trial name
- NCT05826353
- Testing
- Ripasudil
- Where
- 43 sites in United States, Canada and 4 more
- Volunteers
- 110 people
- Sponsor
- Kowa Research Institute, Inc.
Corneal Edema, Corneal Endothelial Dysfunction
Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema
Corneal edema is the most common indication for corneal transplantation, accounting for approximately 70% of penetrating keratoplasty (PK), and 100% of endothelial keratoplasty (EK) procedures annually.
- Conditions
- Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy
- Trial name
- NCT04894110
- Testing
- EO2002, EO2002 low dose, EO2002 mid dose
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emmecell
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.
Fuchs' Corneal Endothelial Dystrophy (FCED)
A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
This is a Phase 1/2 prospective, randomized, double-masked, and vehicle-controlled trial in two parts to evaluate the safety, tolerability, and efficacy of elamipretide topical ophthalmic solution in patients with Fuchs' Corneal…
- Trial name
- SPIFD-101 (NCT02653391)
- Testing
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution
- Where
- 2 sites in United States
- Volunteers
- 22 people
- Sponsor
- Stealth BioTherapeutics Inc.
Cataract, Lens Opacities
Feasibility Investigation of Biometry and Tomography Measurements in a Heterogeneous Patient Cohort
The planned clinical investigation will be conducted to acquire raw data for the development of the algorithm. The data acquisition is intended to obtain first impressions of the potential performance of the changed hardware and…
- Conditions
- Cataract, Lens Opacities, Artificial Lens Implant, Corneal Astigmatism
- Trial name
- BioBase (NCT05458661)
- Testing
- Clinical Prototype BioBase (SN 07 and SN 08)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec AG
Fuchs Endothelial Dystrophy
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could…
- Trial name
- NCT04051463
- Testing
- Netarsudil Ophthalmic Solution
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Price Vision Group
Fuchs' Endothelial Dystrophy
Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration
Subjects with Fuchs dystrophy will be randomized to use either netarsudil or placebo eye drops to determine if the use of netarsudil accelerates migration of host peripheral corneal endothelial cells to restore the central…
- Trial name
- NCT03971357
- Testing
- Netarsudil
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Price Vision Group
Fuchs' Endothelial Corneal Dystrophy
Study to Investigate the Safety and Efficacy of K-321 in Patients With Fuchs Endothelial Corneal Dystrophy (FECD) Following Descemetorhexis
The objective of this study is to investigate the effect of K-321 in patients with Fuchs endothelial corneal dystrophy (FECD) after descemetorhexis.
- Trial name
- NCT04250207
- Testing
- K-321 Solution
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 65 people
- Sponsor
- Kowa Research Institute, Inc.